FR17C0008I1 - (THIO) CARBAMOYL-CYCLOHEXANE DERIVATIVES USED AS D3/D2 RECEPTOR ANTAGONISTS - Google Patents

(THIO) CARBAMOYL-CYCLOHEXANE DERIVATIVES USED AS D3/D2 RECEPTOR ANTAGONISTS

Info

Publication number
FR17C0008I1
FR17C0008I1 FR17C0008C FR17C0008C FR17C0008I1 FR 17C0008 I1 FR17C0008 I1 FR 17C0008I1 FR 17C0008 C FR17C0008 C FR 17C0008C FR 17C0008 C FR17C0008 C FR 17C0008C FR 17C0008 I1 FR17C0008 I1 FR 17C0008I1
Authority
FR
France
Prior art keywords
carbamoyl
thio
receptor antagonists
derivatives used
cyclohexane derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR17C0008C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richter Gedeon Nyrt
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of FR17C0008I1 publication Critical patent/FR17C0008I1/en
Active legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215Radicals derived from nitrogen analogues of carbonic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/04Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
FR17C0008C 2003-08-04 2017-10-10 (THIO) CARBAMOYL-CYCLOHEXANE DERIVATIVES USED AS D3/D2 RECEPTOR ANTAGONISTS Active FR17C0008I1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0302451A HU227534B1 (en) 2003-08-04 2003-08-04 (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
PCT/HU2004/000056 WO2005012266A1 (en) 2003-08-04 2004-05-21 (thio) carbamoyl-cyclohexane derivatives as d3/d2 receptor antagonists

Publications (1)

Publication Number Publication Date
FR17C0008I1 true FR17C0008I1 (en) 2018-12-07

Family

ID=89981557

Family Applications (1)

Application Number Title Priority Date Filing Date
FR17C0008C Active FR17C0008I1 (en) 2003-08-04 2017-10-10 (THIO) CARBAMOYL-CYCLOHEXANE DERIVATIVES USED AS D3/D2 RECEPTOR ANTAGONISTS

Country Status (37)

Country Link
US (2) US7737142B2 (en)
EP (1) EP1663996B1 (en)
JP (1) JP3999806B2 (en)
KR (1) KR100870284B1 (en)
CN (1) CN1829703B (en)
AU (1) AU2004261490B2 (en)
BE (1) BE2017C045I2 (en)
BR (1) BRPI0413283B8 (en)
CA (1) CA2532818C (en)
CY (2) CY1113099T1 (en)
DK (1) DK1663996T3 (en)
EA (1) EA009022B1 (en)
ES (1) ES2389840T3 (en)
FR (1) FR17C0008I1 (en)
HK (1) HK1093494A1 (en)
HR (1) HRP20120715T1 (en)
HU (2) HU227534B1 (en)
IL (1) IL172746A (en)
IS (1) IS2905B (en)
LT (1) LTC1663996I2 (en)
LU (1) LUC00039I2 (en)
MA (1) MA28024A1 (en)
ME (1) ME00564B (en)
MX (1) MXPA06001033A (en)
MY (1) MY142760A (en)
NL (1) NL300913I2 (en)
NO (2) NO334973B1 (en)
NZ (1) NZ544999A (en)
PL (1) PL1663996T3 (en)
PT (1) PT1663996E (en)
RS (1) RS52771B (en)
SI (1) SI1663996T1 (en)
TN (1) TNSN05328A1 (en)
TW (1) TWI327141B (en)
UA (1) UA84022C2 (en)
WO (1) WO2005012266A1 (en)
ZA (1) ZA200601026B (en)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007106746A (en) * 2005-09-13 2007-04-26 Tosoh Corp New aryl homopiperazine compounds, or their salt and production method
EP1870405A1 (en) * 2006-06-22 2007-12-26 Bioprojet Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands
US7795437B2 (en) 2006-10-31 2010-09-14 Hoffmann-La Roche Inc. Ether derivatives
HUP0700269A2 (en) * 2007-04-11 2009-04-28 Richter Gedeon Nyrt Pyrimidinyl-piperazines useful as d3/d2 receptor ligands, pharmaceutical compositions containing them and their use
EP2155200B1 (en) * 2007-05-11 2016-12-07 Richter Gedeon Nyrt. Crystalline form of a carbamoyl-cyclohexane derivative
HU230748B1 (en) * 2007-05-11 2018-02-28 Richter Gedeon Nyrt New piperazine salt and process for its preparation
HUP0700353A2 (en) * 2007-05-18 2008-12-29 Richter Gedeon Nyrt Metabolites of (thio)carbamoyl-cyclohexane derivatives
HUP0700370A2 (en) * 2007-05-24 2009-04-28 Richter Gedeon Nyrt Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment of acute mania
HUP0700369A2 (en) * 2007-05-24 2009-04-28 Richter Gedeon Nyrt Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment in the manufacture of a medicament for the treatment of schizophrenia
DK2185155T3 (en) * 2007-08-03 2018-01-02 Richter Gedeon Nyrt PHARMACEUTICAL COMPOSITIONS WITH DOPAMINE RECEPTOR LIGANDS AND TREATMENT METHODS USING DOPAMINE RECEPTOR LIGANDS
US7875610B2 (en) 2007-12-03 2011-01-25 Richter Gedeon Nyrt. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands
US20110059980A1 (en) * 2008-02-21 2011-03-10 Yasuaki Oobayashi Solid preparation for oral administration
US20090275597A1 (en) * 2008-05-02 2009-11-05 Forest Laboratories Holdings Limited Methods of treating cns disorders
SI2317852T1 (en) 2008-07-16 2015-04-30 Richter Gedeon Nyrt. Pharmaceutical formulations containing dopamine receptor ligands
HU230067B1 (en) * 2008-12-17 2015-06-29 Richter Gedeon Nyrt Novel piperazine salt and preparation method thereof
HUP0800765A2 (en) * 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
HUP0800766A2 (en) * 2008-12-18 2010-11-29 Richter Gedeon Vegyeszet Process for the preparation of piperazine derivatives
WO2010126527A1 (en) * 2009-05-01 2010-11-04 Forest Laboratories Holdings Limited Methods of treating cns disorders
US20110117214A1 (en) * 2009-11-16 2011-05-19 Auspex Pharmaceuticals, Inc. Cyclohexyl urea modulators of d2 receptors and/or d3 receptors
HUP0900790A2 (en) 2009-12-17 2011-09-28 Richter Gedeon Nyrt A new process for the preparation of piperazine and their hydrochloric salts
CN103130737B (en) * 2011-12-05 2015-12-02 江苏恒谊药业有限公司 Hexanaphthene aminated compounds and the application as antipsychotic drug thereof
WO2014031162A1 (en) 2012-08-20 2014-02-27 Forest Laboratories Holdings Limited Crystalline form of carbamoyl-cyclohexane derivatives
ES2734268T3 (en) 2012-10-11 2019-12-05 Southern Res Inst Urea and amide derivatives of aminoalkylpiperazines and use thereof
HU231227B1 (en) 2012-11-29 2022-03-28 Richter Gedeon Nyrt. Trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-n,n-dimethylcarbamoyl-cyclohexylamine for treating negative symptoms of schizophrenia
ITMI20131693A1 (en) * 2013-10-14 2015-04-15 Chemo Res S L DERIVATIVES OF 1,4-CYCLOHEXYLAMINE AND THEIR PREPARATION
CN105085345B (en) * 2015-08-14 2016-09-14 天津小新医药科技有限公司 MENTHOL class P2Y12 receptor antagonist containing nitro and application thereof
CN105085346B (en) * 2015-08-14 2017-03-29 天津小新医药科技有限公司 MENTHOL class P2Y12 receptor antagonist of amino-contained and application thereof
CN105218484B (en) * 2015-09-14 2018-02-23 安徽省逸欣铭医药科技有限公司 Tartaric acid Cariliprazine and preparation method thereof and medical usage
CN106518841B (en) * 2015-09-15 2019-03-05 浙江京新药业股份有限公司 Cyclohexane derivant or its stereoisomer or salt and its preparation and application
CN106543039A (en) * 2015-09-22 2017-03-29 江苏恩华药业股份有限公司 It is a kind of for preparing compound of Cariliprazine and preparation method thereof
CN106560179B (en) * 2015-09-30 2020-02-21 石药集团中奇制药技术(石家庄)有限公司 Carilazine hydrochloride pharmaceutical composition and preparation method thereof
CN105330616B (en) * 2015-12-09 2017-09-26 苏州明锐医药科技有限公司 The preparation method of Cariliprazine
EP3231418A1 (en) 2016-04-14 2017-10-18 Richter Gedeon Nyrt. Granule formulation for oral administration
HU231173B1 (en) 2016-07-08 2021-06-28 Richter Gedeon Nyrt. Industrial procedure for production of cariprazine
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
US10870660B2 (en) 2016-07-28 2020-12-22 Shionogi & Co., Ltd. Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect
CN107793350B (en) * 2016-09-05 2021-06-04 上海医药工业研究院 Arylethylpiperidinyl derivatives and their use for the treatment of schizophrenia
WO2018229794A1 (en) 2017-06-13 2018-12-20 Cipla Limited Amorphous form of cariprazine
HUP1700253A1 (en) 2017-06-13 2019-01-28 Richter Gedeon Nyrt Solid preparations for oral administration
CN111801330B (en) 2018-01-26 2024-04-05 盐野义制药株式会社 Fused ring compounds having dopamine D3 receptor antagonism
WO2019146740A1 (en) 2018-01-26 2019-08-01 塩野義製薬株式会社 Cyclic compound having dopamine d3 receptor antagonism
CN108586389B (en) * 2018-06-29 2020-06-12 成都福柯斯医药技术有限公司 Method for synthesizing Carilazine
CN110872262A (en) 2018-08-29 2020-03-10 上海科胜药物研发有限公司 Synthesis method of cariprazine
CN110872269B (en) * 2018-08-30 2024-06-07 浙江京新药业股份有限公司 Salt of cyclohexane derivative
CN110872270A (en) * 2018-08-30 2020-03-10 浙江京新药业股份有限公司 Salt of cyclohexane derivative
CN111320594A (en) * 2018-12-13 2020-06-23 江苏恩华药业股份有限公司 Carilazine impurity and preparation process and application thereof
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
HU231500B1 (en) 2019-04-10 2024-04-28 Richter Gedeon Nyrt Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
CN112239433B (en) * 2019-07-17 2024-05-14 北京盈科瑞创新药物研究有限公司 Cyclohexane derivative, preparation method and application thereof
CN110372557B (en) * 2019-08-06 2021-05-18 上海勋和医药科技有限公司 Cyclohexanamines D3/D2Partial receptor agonists
MX2022004473A (en) 2019-10-29 2022-05-06 Shanghai Hansoh Biomedical Co Ltd Modifier of four-membered ring derivative, preparation method and application thereof.
JP2023501306A (en) * 2019-11-05 2023-01-18 上▲海▼翰森生物医▲薬▼科技有限公司 Benzothiophene derivative regulators, their preparation and use
HUP2100108A1 (en) 2021-03-12 2022-09-28 Richter Gedeon Nyrt Process for consecutive continuous-flow reductions in the synthesis of medicinally relevant piperazine derivatives using a new device
AU2022266937A1 (en) 2021-04-28 2023-10-19 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Salt containing piperazine polycyclic derivative, crystal form thereof, preparation method therefor, and use thereof
HUP2100259A1 (en) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Controlled release injectable cariprazine formulation
IL311268A (en) 2021-09-15 2024-05-01 Richter Gedeon Nyrt PROCESS TO PRODUCE (1r,4r)-4-SUBSTITUTED CYCLOHEXANE-1-AMINES
HUP2200312A1 (en) 2022-08-05 2024-02-28 Richter Gedeon Nyrt Orally disintegrating pharmaceutical tablet containing cariprazine
WO2024072930A1 (en) * 2022-09-30 2024-04-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dopamine d3/d2 receptor partial agonists for the treatment of neuropsychiatric disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997011070A1 (en) 1995-09-22 1997-03-27 Warner-Lambert Company Substituted cyclohexylamines as central nervous system agents
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
RU2230740C2 (en) 1998-03-31 2004-06-20 Акадиа Фармасьютикалз, Инк. Derivatives of nitrogen-containing heterocyclic compounds and pharmaceutical composition based on thereof
SE9802208D0 (en) 1998-06-22 1998-06-22 Astra Pharma Inc Novel compounds
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
CY1113099T1 (en) 2016-04-13
CA2532818A1 (en) 2005-02-10
BRPI0413283B1 (en) 2021-10-05
IS8199A (en) 2005-12-22
BRPI0413283A (en) 2006-10-10
MY142760A (en) 2010-12-31
JP2007501215A (en) 2007-01-25
HU0302451D0 (en) 2003-10-28
EP1663996A1 (en) 2006-06-07
CY2017032I2 (en) 2018-02-14
ME00564A (en) 2011-12-20
NO2017051I1 (en) 2017-10-09
ME00564B (en) 2011-12-20
KR100870284B1 (en) 2008-11-25
AU2004261490B2 (en) 2008-08-21
NL300913I2 (en) 2017-12-20
NO334973B1 (en) 2014-08-11
AU2004261490A1 (en) 2005-02-10
CY2017032I1 (en) 2018-02-14
EA009022B1 (en) 2007-10-26
HRP20120715T1 (en) 2012-09-30
NZ544999A (en) 2009-07-31
PL1663996T3 (en) 2012-11-30
KR20060058096A (en) 2006-05-29
CN1829703B (en) 2011-06-08
US20100240640A1 (en) 2010-09-23
TNSN05328A1 (en) 2007-07-10
LUC00039I2 (en) 2017-12-20
ZA200601026B (en) 2007-05-30
HUS1700044I1 (en) 2017-11-28
HK1093494A1 (en) 2007-03-02
TW200505874A (en) 2005-02-16
JP3999806B2 (en) 2007-10-31
CA2532818C (en) 2009-07-14
TWI327141B (en) 2010-07-11
US20060229297A1 (en) 2006-10-12
ES2389840T3 (en) 2012-11-02
EP1663996B1 (en) 2012-06-20
BRPI0413283B8 (en) 2021-10-05
EA200600364A1 (en) 2006-06-30
LTPA2017027I1 (en) 2017-09-25
BE2017C045I2 (en) 2023-08-09
IS2905B (en) 2014-10-15
MXPA06001033A (en) 2006-04-24
IL172746A (en) 2016-02-29
LTC1663996I2 (en) 2018-05-25
HU227534B1 (en) 2011-08-29
NO20061076L (en) 2006-03-06
LUC00039I1 (en) 2017-10-16
HUP0302451A2 (en) 2005-05-30
SI1663996T1 (en) 2012-10-30
IL172746A0 (en) 2006-04-10
NO2017051I2 (en) 2018-11-19
RS52771B (en) 2013-10-31
RS20060041A (en) 2009-11-10
CN1829703A (en) 2006-09-06
MA28024A1 (en) 2006-07-03
UA84022C2 (en) 2008-09-10
WO2005012266A1 (en) 2005-02-10
DK1663996T3 (en) 2012-10-01
US7737142B2 (en) 2010-06-15
PT1663996E (en) 2012-09-24
NL300913I1 (en) 2017-11-23

Similar Documents

Publication Publication Date Title
FR17C0008I1 (en) (THIO) CARBAMOYL-CYCLOHEXANE DERIVATIVES USED AS D3/D2 RECEPTOR ANTAGONISTS
FR20C1039I2 (en) DERIVATIVES OF UK-2A
FR22C1036I1 (en) PYRIMIDINE DERIVATIVES AS HIV INHIBITOR
FR18C1024I1 (en) HETEROCYCLOCARBOXAMIDE DERIVATIVES
MA27680A1 (en) 4-PHENYL-PYRIDINE DERIVATIVES AS NEUROKININ-1 RECEPTOR ANTAGONISTS
MA26958A1 (en) 2-PHENYLAMINOIMIDAZOLINE DERIVATIVES PHENYL KETONE SUBSTITUTED AS IP ANTAGONISTS
FR15C0086I2 (en) HYDROXAMATE DERIVATIVES AS DESACETYLASE INHIBITORS
NO20041504L (en) Lactam derivatives as antagonists of human 11CBY receptors.
NO20043022L (en) 5,6-diaryl-pyrazine-2-amide derivatives as CB1 antagonists
FR15C0068I2 (en) DIAMINE DERIVATIVES
MA27679A1 (en) CARBOXYLIC ACID DERIVATIVES AS IP ANTAGONISTS
PT1349839E (en) PHENYLETENYL OR PHENYLETINYL DERIVATIVES AS ANTAGONISTS OF THE GLUTAMATE RECEPTOR
MA28479B1 (en) HETEROARYLAMINOPYRAZOLE DERIVATIVES FOR TREATING DIABETES
BRPI0313478A2 (en) endoscope sleeve dispenser
MA26959A1 (en) 3-AROYLINDOLE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS
MA26933A1 (en) 4-PHENYL-PYRIDINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS 1.
DK1440059T3 (en) 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists
FR2813756B1 (en) DILUENT FOR THE CONSERVATION OF SWINE SPERMATOZOIDES
MA27046A1 (en) NEW OXAZOLIDINON DERIVATIVES AS ANTIBACTERIAL AGENTS.
MA28819B1 (en) KYNURENIC ACID AMIDIC DERIVATIVES AS NR2B RECEPTOR ANTAGONISTS
MA28177A1 (en) 7- [4- (4-CHLOROBENZYLOXY) BENZENESULFONYL] -8-METHOXY-3-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINIUM MALEATE OR TOSYLATE AS ANTIPSYCHOTIC AGENTS
ATE309994T1 (en) ALKOXYCARBONYLAMINOBENZOIC ACID OR ALKOXYCARBONYLAMINOTETRAZOLYLPHENYL DERIVATIVES AS IP ANTAGONISTS
MA27094A1 (en) TRIAZOLO-QUINOLINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR LIGANDS.
FR2833596B1 (en) PROCESS FOR THE PREPARATION OF ECHINOCANDIN DERIVATIVES
DE60214408D1 (en) 5-METHOXY-8-ARYL-i1,2,4öTRIAZOLOi1,5-AOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS